Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This registry study aims to collect data on efficacy and safety of different treatments of benign prostatic enlargement (BPE) and lower urinary tract symptoms associated with benign prostatic hyperplasia (BPH-LUTS).
This registry study aims to collect data on efficacy and safety of different treatments of benign prostatic enlargement (BPE) and lower urinary tract symptoms associated with benign prostatic hyperplasia (BPH-LUTS).
Clinical, patient reported and imaging data that are assessed in clinical routine will be prospectively collected. All patients that are treated for BPE / BPH-LUTS at our institution will be included if they provide written informed consent.
This registry enables us to compare novel treatment option (e.g. prostatic artery embolization; PAE) to established interventions (e.g., TURP, HoLEP, open prostatectomy, ThuLEP, Thulium laser vaporization, TUIP) regarding safety and efficacy.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| PAE | Men with BPH - LUTS BPE who have opted for PAE and have consented to take part in the Register Study. |
| |
| TURP | Men with BPH - LUTS BPE who have opted for TURP and have consented to take part in the Register Study. |
| |
| Other | Men with BPH - LUTS BPE who have opted for other treatment options (e.g., holmium laser enucleation of the prostate, open prostatectomy, thulium laser vaporization, resection or enucleation, transurethral incision of the prostate) and have consented to take part in the Register Study. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| PAE | Procedure | Prostatic artery embolization |
| |
| TURP |
| Measure | Description | Time Frame |
|---|---|---|
| Reduction of Lower Urinary Tract Symptoms | Change of total score of International Prostate Symptoms Score (IPSS; range 0 points (no symptoms) to 35 points (severe symptoms)) | baseline to 1 year |
| Changes of free urinary flow rate | Measurement of urinary stream (mL/s) by urinary flow rate measurement | baseline to 1 year |
| Changes of post void residual urine | Measurement of post void residual urine (mL) by transabdominal ultrasound | baseline to 1 year |
| Measure | Description | Time Frame |
|---|---|---|
| Reduction of Lower Urinary Tract Symptoms | Change of total score of International Prostate Symptoms Score (IPSS; range 0 points (no symptoms) to 35 points (severe symptoms)) | baseline to 6 weeks |
| Reduction of Lower Urinary Tract Symptoms |
Not provided
Inclusion Criteria:
Exclusion Criteria:
-Cognitive impairment not allowing Informed Consent or adequate data assessment.
Not provided
Not provided
Not provided
All patients treated for BPH / LUTS / prostatic obstruction at the urological department of KSSG
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Dominik Abt, MD | Contact | +41 71 494 14 16 | dominik.abt@kssg.ch | |
| Gautier Müllhaupt, MD | Contact | +41 71 494 14 16 | Gautier.muellhaupt@kssg.ch |
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| St. Gallen Cantonal Hospital | Recruiting | Sankt Gallen | Canton of St. Gallen | 9007 | Switzerland |
Requests for an anonymized, full data set of physician-level data and statistical code will be considered if the proposed use aligns with public good purposes, does not conflict with other requests, or planned use by the trial steering committee and is contingent on approval from the local ethics committee (EKOS). Requests can be addressed to the corresponding author.
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D059411 | Lower Urinary Tract Symptoms |
| D011470 | Prostatic Hyperplasia |
| ID | Term |
|---|---|
| D020924 | Urological Manifestations |
| D012816 | Signs and Symptoms |
| D013568 | Pathological Conditions, Signs and Symptoms |
| D011469 | Prostatic Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| D020728 | Transurethral Resection of Prostate |
| ID | Term |
|---|---|
| D011468 | Prostatectomy |
| D013521 | Urologic Surgical Procedures, Male |
| D013520 | Urologic Surgical Procedures |
| D013519 | Urogenital Surgical Procedures |
Not provided
Not provided
Not provided
Not provided
Not provided
| Procedure |
Transurethral resection of the prostate |
|
| Other | Procedure | Other surgical procedures for BPH treatment including holmium laser enucleation of the prostate, open prostatectomy, thulium laser vaporization, resection or enucleation, transurethral incision of the prostate |
|
Change of total score of International Prostate Symptoms Score (IPSS; range 0 points (no symptoms) to 35 points (severe symptoms))
| baseline to 12 weeks |
| Reduction of Lower Urinary Tract Symptoms | Change of total score of International Prostate Symptoms Score (IPSS; range 0 points (no symptoms) to 35 points (severe symptoms)) | baseline to 6 months |
| Reduction of Lower Urinary Tract Symptoms | Change of total score of International Prostate Symptoms Score (IPSS; range 0 points (no symptoms) to 35 points (severe symptoms)) | baseline to 2 years |
| Reduction of Lower Urinary Tract Symptoms | Change of total score of International Prostate Symptoms Score (IPSS; range 0 points (no symptoms) to 35 points (severe symptoms)) | baseline to 5 years |
| Changes of free urinary flow rate | Measurement of urinary stream (mL/s) by urinary flow rate measurement | baseline to 6 weeks |
| Changes of free urinary flow rate | Measurement of urinary stream (mL/s) by urinary flow rate measurement | baseline to 12 weeks |
| Changes of free urinary flow rate | Measurement of urinary stream (mL/s) by urinary flow rate measurement | baseline to 6 months |
| Changes of free urinary flow rate | Measurement of urinary stream (mL/s) by urinary flow rate measurement | baseline to 2 years |
| Changes of free urinary flow rate | Measurement of urinary stream (mL/s) by urinary flow rate measurement | baseline to 5 years |
| Changes of post void residual urine | Measurement of post void residual urine (mL) by transabdominal ultrasound | baseline to 6 weeks |
| Changes of post void residual urine | Measurement of post void residual urine (mL) by transabdominal ultrasound | baseline to 12 weeks |
| Changes of post void residual urine | Measurement of post void residual urine (mL) by transabdominal ultrasound | baseline to 6 months |
| Changes of post void residual urine | Measurement of post void residual urine (mL) by transabdominal ultrasound | baseline to 2 years |
| Changes of post void residual urine | Measurement of post void residual urine (mL) by transabdominal ultrasound | baseline to 5 years |
| Rate of local reinterventions | Assessment of number and type of reinterventions for prostate and bladder problems | during 5 year study period |
| Rate of local medical treatment for BPH-LUTS | Assessment of number and type of medical treatments for prostate and bladder problems | during 5 year study period |
| Adverse Events | Assessment of adverse events that are at least possibly related to study procedure according to Clavien-Dindo and CTCAE | 6 weeks after intervention |
| Adverse Events | Assessment of adverse events that are at least possibly related to study procedure according to Clavien-Dindo and CTCAE | 12 weeks after intervention |
| Adverse Events | Assessment of adverse events that are at least possibly related to study procedure according to Clavien-Dindo and CTCAE | 6 months after intervention |
| Adverse Events | Assessment of adverse events that are at least possibly related to study procedure according to Clavien-Dindo and CTCAE | 1 year after intervention |
| Adverse Events | Assessment of adverse events that are at least possibly related to study procedure according to Clavien-Dindo and CTCAE | 2 years after intervention |
| Adverse Events | Assessment of adverse events that are at least possibly related to study procedure according to Clavien-Dindo and CTCAE | 5 years after intervention |
| Urodynamic changes | Results of pressure flow studies if assessed for clinical reasons during the study period | during 5 year study period |
| Change of prostate size | Measurement of prostate size (using MRI or ultrasound) in mL | 6 weeks after intervention |
| Change of prostate size | Measurement of prostate size (using MRI or ultrasound) in mL | 12 weeks after intervention |
| Change of prostate size | Measurement of prostate size (using MRI or ultrasound) in mL | 6 moths after intervention |
| Change of prostate size | Measurement of prostate size (using MRI or ultrasound) in mL | 1 year after intervention |
| Change of prostate size | Measurement of prostate size (using MRI or ultrasound) in mL | 2 years after intervention |
| Change of prostate size | Measurement of prostate size (using MRI or ultrasound) in mL | 5 years after intervention |
| PSA | Changes of Prostate Specific Antigen (PSA, ng/mL) | 6 weeks after intervention |
| PSA | Changes of Prostate Specific Antigen (PSA, ng/mL) | 12 weeks after intervention |
| PSA | Changes of Prostate Specific Antigen (PSA, ng/mL) | 6 moths after intervention |
| PSA | Changes of Prostate Specific Antigen (PSA, ng/mL) | 1 year after intervention |
| PSA | Changes of Prostate Specific Antigen (PSA, ng/mL) | 2 years after intervention |
| PSA | Changes of Prostate Specific Antigen (PSA, ng/mL) | 5 years after intervention |
| Assessment of erectile function | Assessment of IIEF-5 questionnaire | 6 weeks after intervention |
| Assessment of erectile function | Assessment of IIEF-5 questionnaire | 12 weeks after intervention |
| Assessment of erectile function | Assessment of IIEF-5 questionnaire | 6 moths after intervention |
| Assessment of erectile function | Assessment of IIEF-5 questionnaire | 1 year after intervention |
| Assessment of erectile function | Assessment of IIEF-5 questionnaire | 2 years after intervention |
| Assessment of erectile function | Assessment of IIEF-5 questionnaire | 5 years after intervention |
| Reduction of Prostate symptoms | Change of CPSI total score (Chronic prostatitis symptoms score; range 0 points (no symptoms) to 43 points (severe symptoms)) | baseline to 6 weeks |
| Reduction of Prostate symptoms | Change of CPSI total score (Chronic prostatitis symptoms score; range 0 points (no symptoms) to 43 points (severe symptoms)) | baseline to 12 weeks |
| Reduction of Prostate symptoms | Change of CPSI total score (Chronic prostatitis symptoms score; range 0 points (no symptoms) to 43 points (severe symptoms)) | baseline to 6 moths |
| Reduction of Prostate symptoms | Change of CPSI total score (Chronic prostatitis symptoms score; range 0 points (no symptoms) to 43 points (severe symptoms)) | baseline to 1 year |
| Reduction of Prostate symptoms | Change of CPSI total score (Chronic prostatitis symptoms score; range 0 points (no symptoms) to 43 points (severe symptoms)) | baseline to 2 years |
| Reduction of Prostate symptoms | Change of CPSI total score (Chronic prostatitis symptoms score; range 0 points (no symptoms) to 43 points (severe symptoms)) | baseline to 5 years |
| Ejaculatory function | Assessment of ejaculatory function according to CTCAE | 6 weeks after intervention |
| Ejaculatory function | Assessment of ejaculatory function according to CTCAE | 12 weeks after intervention |
| Ejaculatory function | Assessment of ejaculatory function according to CTCAE | 6 moths after intervention |
| Ejaculatory function | Assessment of ejaculatory function according to CTCAE | 1 year after intervention |
| Ejaculatory function | Assessment of ejaculatory function according to CTCAE | 2 years after intervention |
| Ejaculatory function | Assessment of ejaculatory function according to CTCAE | 5 years after intervention |
| D005832 | Genital Diseases, Male |
| D000091662 | Genital Diseases |
| D000091642 | Urogenital Diseases |
| D052801 | Male Urogenital Diseases |
| D013514 | Surgical Procedures, Operative |